ABT-089

DRUG11 trials

Sponsors

Abbott, AbbVie (prior sponsor, Abbott), University of Pennsylvania

Conditions

Alzheimer's DiseaseAttention Deficit Hyperactivity DisorderAttention-Deficit/Hyperactivity DisorderNicotine Addiction

Phase 2

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

TerminatedNCT00069849

AbbottAlzheimer's Disease

Start: 2003-07-31Target: 64Updated: 2006-09-04

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

CompletedNCT00391729

AbbottAttention-Deficit/Hyperactivity Disorder

Start: 2006-10-31End: 2007-06-30Updated: 2011-10-18

A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)

CompletedNCT00443391

AbbVie (prior sponsor, Abbott)Attention Deficit Hyperactivity Disorder

Start: 2007-02-28End: 2008-10-31Updated: 2013-01-18

A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

CompletedNCT00528697

AbbVie (prior sponsor, Abbott)Attention-Deficit/Hyperactivity Disorder

Start: 2007-09-30End: 2008-04-30Updated: 2013-01-29

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

TerminatedNCT00554385

AbbottAttention-Deficit/Hyperactivity Disorder

Start: 2007-11-30Updated: 2011-08-23

Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

TerminatedNCT00555204

AbbottAlzheimer's Disease

Start: 2007-11-30Updated: 2011-08-23

Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

CompletedNCT00640185

AbbVie (prior sponsor, Abbott)Attention-Deficit/Hyperactivity Disorder

Start: 2008-03-31End: 2008-08-31Updated: 2013-01-18

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

CompletedNCT00640419

AbbVie (prior sponsor, Abbott)Attention-Deficit/Hyperactivity Disorder

Start: 2008-03-31End: 2008-07-31Updated: 2013-01-18

Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

CompletedNCT00686933

AbbVie (prior sponsor, Abbott)Attention-Deficit/Hyperactivity Disorder

Start: 2008-05-31End: 2008-10-31Updated: 2013-01-21

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

TerminatedNCT00809510

AbbottAlzheimer's Disease

Start: 2009-01-31Updated: 2011-09-02

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

TerminatedNCT01756053

University of PennsylvaniaNicotine Addiction

Start: 2013-03-31End: 2014-01-31Updated: 2014-10-29

Related Papers

Lecanemab for Patients With Early Alzheimer Disease

JAMA Network Open2023-04-1119 citations

A randomized pilot study of the efficacy and safety of ABT-089, a novel α4β2 neuronal nicotinic receptor agonist, in adults with attention-deficit/hyperactivity disorder.

2012-06-0116 citations